| Identification | Back Directory | [Name]
GNE-6640 | [CAS]
2009273-67-8 | [Synonyms]
CS-2824
GNE-6641
GNE-6640;GNE 6640;GNE6640;2009273-67-8
Phenol, 4-[2-amino-4-ethyl-5-(1H-indazol-5-yl)-3-pyridinyl]- | [Molecular Formula]
C20H18N4O | [MDL Number]
MFCD31807618 | [MOL File]
2009273-67-8.mol | [Molecular Weight]
330.38 |
| Chemical Properties | Back Directory | [Boiling point ]
595.5±50.0 °C(Predicted) | [density ]
1.308±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMF:1.0(Max Conc. mg/mL);3.03(Max Conc. mM)
DMSO:3.0(Max Conc. mg/mL);9.08(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:2):0.3(Max Conc. mg/mL);0.91(Max Conc. mM) | [form ]
A solid | [pka]
8.23±0.15(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
GNE-6640 is a selective and non-covalent inhibitor of ubiquitin epecific peptidase 7 (USP7), with IC50 values of 0.75 μM, 0.43 μM, 20.3 μM and 0.23 μM for full length USP7, USP7 catalytic domain, full length USP47 and Ub-MDM2, respectively[1][2]. | [References]
[1] Kategaya L, et al. USP7 small-molecule inhibitors interfere with ubiquitin binding. Nature. 2017 Oct 26;550(7677):534-538. DOI:10.1038/nature24006
[2] Tanguturi P, et al. The role of deubiquitinating enzymes in cancer drug resistance. Cancer Chemother Pharmacol. 2020 Apr;85(4):627-639. DOI:10.1007/s00280-020-04046-8 |
|
|